Triparanol

Summary

Triparanol (CHEMBL187709) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 438 Da · C27H32ClNO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL187709
Name	Triparanol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6536
Molecular formula	C27H32ClNO2
Molecular weight	438
InChIKey	SYHDSBBKRLVLFF-UHFFFAOYSA-N

SMILES: CCN(CC)CCOC1=CC=C(C=C1)C(CC2=CC=C(C=C2)Cl)(C3=CC=C(C=C3)C)O

IUPAC name: 2-(4-chlorophenyl)-1-[4-[2-(diethylamino)ethoxy]phenyl]-1-(4-methylphenyl)ethanol

Also known as: NSC-65345, Triparanol, SID29217665, SID50111719, triparanol, SID144205821, SID170466640, TRIPARANOL

Patent coverage: 618 distinct patent families (2,314 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Nuclear receptor ROR-gamma, 4’-phosphopantetheinyl transferase ffp, Sigma non-opioid intracellular receptor 1, C-8 sterol isomerase ERG2, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P32352	8.7	Ki	2	nM	CHEMBL_ACT_1483962
SIGMAR1	8.1	Ki	8	nM	CHEMBL_ACT_1483863
EBP	7.96	Ki	11	nM	CHEMBL_ACT_1483862
P51450	5.4	Potency	3981	nM	CHEMBL_ACT_4759322

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).